A clinical study in China used sorafenib and toad extract (Huamao) to treat HCC and obtained a higher effective rate than a single drug, and the combined group had more significant improvements in WBC, TBIL, and ALT indicators, a higher quality of life for patients, and weaker pain (Feng et al., 2012). The gene discussed is GPT; the disease is hepatocellular carcinoma.